Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Tislelizumab for Resectable SCLC
NCT07109401Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in small cell lung cancer (SCLC), sponsored by Fudan University. Started Mar 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07109401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07109401.